| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 18 | 2023 | 1188 | 3.130 |
Why?
|
| Intermittent Claudication | 6 | 2023 | 309 | 2.740 |
Why?
|
| Stents | 22 | 2021 | 3280 | 1.960 |
Why?
|
| Angioplasty, Balloon, Coronary | 14 | 2020 | 1873 | 1.580 |
Why?
|
| Lower Extremity | 11 | 2023 | 1158 | 1.530 |
Why?
|
| Coronary Artery Disease | 31 | 2024 | 6487 | 1.510 |
Why?
|
| Drug-Eluting Stents | 6 | 2023 | 753 | 1.460 |
Why?
|
| Femoral Artery | 7 | 2023 | 845 | 1.410 |
Why?
|
| Ticlopidine | 5 | 2016 | 899 | 1.400 |
Why?
|
| Ischemia | 8 | 2023 | 1907 | 1.380 |
Why?
|
| Heptanoic Acids | 9 | 2009 | 343 | 1.340 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2023 | 3068 | 1.280 |
Why?
|
| Acute Coronary Syndrome | 7 | 2023 | 2337 | 1.230 |
Why?
|
| Endovascular Procedures | 6 | 2023 | 1979 | 1.210 |
Why?
|
| Endothelium, Vascular | 30 | 2014 | 4456 | 1.050 |
Why?
|
| Ultrasonography, Interventional | 12 | 2019 | 1486 | 1.050 |
Why?
|
| Coronary Disease | 20 | 2008 | 6077 | 1.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2012 | 3255 | 1.040 |
Why?
|
| Pyrroles | 9 | 2009 | 1146 | 0.970 |
Why?
|
| Angioplasty, Balloon | 7 | 2020 | 653 | 0.970 |
Why?
|
| Leg | 3 | 2016 | 1116 | 0.970 |
Why?
|
| Angioplasty | 4 | 2020 | 364 | 0.900 |
Why?
|
| Cardiology | 7 | 2016 | 1668 | 0.890 |
Why?
|
| Angina Pectoris | 6 | 2009 | 977 | 0.860 |
Why?
|
| Myocardial Infarction | 24 | 2024 | 11727 | 0.830 |
Why?
|
| C-Reactive Protein | 9 | 2013 | 3778 | 0.770 |
Why?
|
| Vasodilation | 10 | 2019 | 944 | 0.730 |
Why?
|
| Anticholesteremic Agents | 9 | 2009 | 979 | 0.700 |
Why?
|
| Coronary Artery Bypass | 8 | 2024 | 2289 | 0.690 |
Why?
|
| Angina, Unstable | 5 | 2004 | 926 | 0.680 |
Why?
|
| Metals | 3 | 2015 | 719 | 0.680 |
Why?
|
| Arteriosclerosis | 14 | 2004 | 1092 | 0.670 |
Why?
|
| Vascular Patency | 6 | 2023 | 886 | 0.660 |
Why?
|
| Persian Gulf Syndrome | 1 | 2019 | 45 | 0.660 |
Why?
|
| Vascular Resistance | 4 | 2019 | 936 | 0.650 |
Why?
|
| Veterans | 2 | 2023 | 2519 | 0.640 |
Why?
|
| Coronary Vasospasm | 2 | 2014 | 88 | 0.640 |
Why?
|
| Coronary Stenosis | 4 | 2018 | 834 | 0.620 |
Why?
|
| Popliteal Artery | 3 | 2023 | 317 | 0.580 |
Why?
|
| Withholding Treatment | 1 | 2021 | 599 | 0.570 |
Why?
|
| Coronary Vessels | 13 | 2014 | 3107 | 0.560 |
Why?
|
| Coronary Angiography | 16 | 2014 | 4577 | 0.550 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2011 | 793 | 0.540 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 875 | 0.510 |
Why?
|
| Cholesterol, LDL | 13 | 2009 | 2356 | 0.500 |
Why?
|
| Microvessels | 1 | 2019 | 544 | 0.490 |
Why?
|
| Licensure, Medical | 1 | 2014 | 62 | 0.480 |
Why?
|
| Acetylcholine | 4 | 2014 | 621 | 0.470 |
Why?
|
| Treatment Outcome | 35 | 2024 | 63114 | 0.470 |
Why?
|
| Vascular Surgical Procedures | 4 | 2017 | 1475 | 0.460 |
Why?
|
| Atrial Fibrillation | 6 | 2024 | 5034 | 0.450 |
Why?
|
| Hypolipidemic Agents | 5 | 2002 | 604 | 0.450 |
Why?
|
| Vitamin E | 6 | 2006 | 869 | 0.440 |
Why?
|
| Specialty Boards | 1 | 2014 | 227 | 0.440 |
Why?
|
| Myocardial Revascularization | 2 | 2011 | 841 | 0.430 |
Why?
|
| Myocardial Ischemia | 8 | 2014 | 2148 | 0.430 |
Why?
|
| Aortic Rupture | 1 | 2015 | 310 | 0.420 |
Why?
|
| Hemorrhage | 6 | 2024 | 3461 | 0.420 |
Why?
|
| Amlodipine | 1 | 2012 | 83 | 0.410 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 850 | 0.410 |
Why?
|
| Drug Therapy, Combination | 8 | 2023 | 6489 | 0.410 |
Why?
|
| Humans | 158 | 2024 | 744343 | 0.400 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 4933 | 0.400 |
Why?
|
| Coronary Sinus | 1 | 2012 | 87 | 0.390 |
Why?
|
| Serum Amyloid A Protein | 3 | 2013 | 121 | 0.390 |
Why?
|
| Aspirin | 3 | 2023 | 3282 | 0.390 |
Why?
|
| Risk Factors | 39 | 2023 | 72290 | 0.390 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2012 | 124 | 0.380 |
Why?
|
| Septal Occluder Device | 1 | 2011 | 128 | 0.380 |
Why?
|
| Ascorbic Acid | 6 | 2006 | 651 | 0.370 |
Why?
|
| Blood Vessels | 1 | 2016 | 1125 | 0.370 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 1405 | 0.370 |
Why?
|
| Coronary Thrombosis | 2 | 2020 | 495 | 0.360 |
Why?
|
| Enalapril | 1 | 2012 | 327 | 0.360 |
Why?
|
| Disease Management | 4 | 2017 | 2459 | 0.360 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 814 | 0.360 |
Why?
|
| Mastitis | 2 | 2001 | 41 | 0.360 |
Why?
|
| Cholesterol | 8 | 1999 | 2917 | 0.350 |
Why?
|
| Foreign-Body Migration | 1 | 2011 | 222 | 0.350 |
Why?
|
| Aorta, Thoracic | 2 | 2015 | 1082 | 0.350 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2020 | 549 | 0.340 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2009 | 23 | 0.340 |
Why?
|
| Subclavian Artery | 1 | 2009 | 130 | 0.340 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2015 | 686 | 0.330 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2012 | 550 | 0.330 |
Why?
|
| Foramen Ovale, Patent | 1 | 2011 | 223 | 0.330 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1107 | 0.320 |
Why?
|
| Blood Flow Velocity | 5 | 2019 | 1423 | 0.320 |
Why?
|
| Embolism | 1 | 2011 | 408 | 0.320 |
Why?
|
| Limb Salvage | 3 | 2023 | 433 | 0.320 |
Why?
|
| Propensity Score | 4 | 2016 | 1781 | 0.310 |
Why?
|
| Vascular Diseases | 1 | 2016 | 1161 | 0.310 |
Why?
|
| Endothelin-1 | 3 | 2009 | 314 | 0.300 |
Why?
|
| Antioxidants | 6 | 2006 | 1663 | 0.300 |
Why?
|
| Proportional Hazards Models | 9 | 2024 | 12354 | 0.300 |
Why?
|
| Prosthesis Design | 4 | 2016 | 2110 | 0.290 |
Why?
|
| Male | 85 | 2023 | 350118 | 0.290 |
Why?
|
| Vasomotor System | 6 | 2005 | 209 | 0.290 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2009 | 277 | 0.280 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 1351 | 0.280 |
Why?
|
| Antihypertensive Agents | 3 | 2012 | 2046 | 0.280 |
Why?
|
| Multivariate Analysis | 10 | 2016 | 12245 | 0.270 |
Why?
|
| Endarterectomy, Carotid | 1 | 2011 | 546 | 0.270 |
Why?
|
| Arteries | 3 | 2018 | 1119 | 0.260 |
Why?
|
| CD40 Ligand | 2 | 2004 | 526 | 0.260 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 933 | 0.260 |
Why?
|
| Time Factors | 20 | 2020 | 40075 | 0.260 |
Why?
|
| Middle Aged | 67 | 2021 | 213383 | 0.260 |
Why?
|
| Cause of Death | 1 | 2015 | 3584 | 0.250 |
Why?
|
| Stroke | 5 | 2024 | 9981 | 0.250 |
Why?
|
| Ankle Brachial Index | 2 | 2018 | 154 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 9959 | 0.250 |
Why?
|
| Upper Extremity | 1 | 2009 | 648 | 0.250 |
Why?
|
| Electrocardiography | 9 | 2013 | 6442 | 0.240 |
Why?
|
| Advisory Committees | 3 | 2017 | 775 | 0.240 |
Why?
|
| American Heart Association | 3 | 2017 | 1056 | 0.230 |
Why?
|
| Carotid Stenosis | 1 | 2011 | 854 | 0.230 |
Why?
|
| Vasoconstriction | 2 | 2009 | 597 | 0.230 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2013 | 1261 | 0.230 |
Why?
|
| Coronary Circulation | 7 | 2009 | 1572 | 0.220 |
Why?
|
| Fibrinolytic Agents | 2 | 2023 | 2158 | 0.220 |
Why?
|
| Coronary Restenosis | 2 | 2003 | 424 | 0.220 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 1 | 2002 | 25 | 0.220 |
Why?
|
| Lovastatin | 2 | 2002 | 120 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 7279 | 0.220 |
Why?
|
| Aged | 48 | 2023 | 163280 | 0.220 |
Why?
|
| Anticoagulants | 5 | 2024 | 4599 | 0.220 |
Why?
|
| Nitric Oxide | 6 | 2001 | 2132 | 0.210 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 1637 | 0.210 |
Why?
|
| Female | 70 | 2021 | 380194 | 0.210 |
Why?
|
| Postoperative Care | 2 | 2021 | 1486 | 0.200 |
Why?
|
| Syndrome | 6 | 2003 | 3251 | 0.200 |
Why?
|
| Breast Feeding | 2 | 2001 | 1338 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 2208 | 0.190 |
Why?
|
| Boston | 3 | 2023 | 9313 | 0.190 |
Why?
|
| Constriction, Pathologic | 4 | 2018 | 1107 | 0.190 |
Why?
|
| Biomedical Research | 2 | 2016 | 3309 | 0.190 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 1889 | 0.190 |
Why?
|
| Clinical Competence | 3 | 2014 | 4687 | 0.180 |
Why?
|
| Atherosclerosis | 4 | 2014 | 3445 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2009 | 1786 | 0.180 |
Why?
|
| Diet Surveys | 2 | 1997 | 1173 | 0.180 |
Why?
|
| Saphenous Vein | 2 | 2020 | 532 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2011 | 2708 | 0.180 |
Why?
|
| Australia | 8 | 2013 | 1170 | 0.180 |
Why?
|
| Brachial Artery | 5 | 2004 | 369 | 0.180 |
Why?
|
| Lipoproteins, LDL | 6 | 2005 | 640 | 0.180 |
Why?
|
| New South Wales | 6 | 2001 | 66 | 0.180 |
Why?
|
| Laboratories | 3 | 2012 | 463 | 0.170 |
Why?
|
| United States | 16 | 2021 | 69872 | 0.170 |
Why?
|
| Fibrinogen | 2 | 1993 | 894 | 0.170 |
Why?
|
| Endpoint Determination | 2 | 2013 | 601 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2013 | 5317 | 0.170 |
Why?
|
| Secondary Prevention | 3 | 2012 | 1530 | 0.170 |
Why?
|
| Recurrence | 8 | 2013 | 8340 | 0.160 |
Why?
|
| Hypercholesterolemia | 6 | 2003 | 1151 | 0.160 |
Why?
|
| Emergency Treatment | 2 | 2012 | 517 | 0.160 |
Why?
|
| Nitroglycerin | 5 | 2002 | 325 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2024 | 2073 | 0.160 |
Why?
|
| Risk Assessment | 9 | 2019 | 23338 | 0.150 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2023 | 531 | 0.150 |
Why?
|
| Brain Ischemia | 1 | 2011 | 3265 | 0.150 |
Why?
|
| Acute Disease | 6 | 2003 | 7149 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5751 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 3537 | 0.140 |
Why?
|
| Quality of Life | 4 | 2022 | 12804 | 0.140 |
Why?
|
| Logistic Models | 5 | 2016 | 13408 | 0.140 |
Why?
|
| Dietary Fats | 2 | 1997 | 2017 | 0.140 |
Why?
|
| Immunodiffusion | 2 | 1993 | 163 | 0.140 |
Why?
|
| Veterans Disability Claims | 1 | 2015 | 15 | 0.140 |
Why?
|
| Heart Transplantation | 6 | 2009 | 3110 | 0.140 |
Why?
|
| Analysis of Variance | 3 | 2015 | 6365 | 0.140 |
Why?
|
| Societies, Scientific | 1 | 2017 | 220 | 0.140 |
Why?
|
| Puerperal Disorders | 1 | 1998 | 275 | 0.130 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 1997 | 226 | 0.130 |
Why?
|
| Predictive Value of Tests | 10 | 2018 | 15076 | 0.130 |
Why?
|
| Risk | 4 | 2009 | 9687 | 0.130 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2018 | 269 | 0.130 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 39050 | 0.130 |
Why?
|
| Lipoprotein(a) | 3 | 2009 | 435 | 0.130 |
Why?
|
| Heart Failure | 3 | 2024 | 10900 | 0.130 |
Why?
|
| Cardiovascular Diseases | 3 | 2012 | 15165 | 0.130 |
Why?
|
| Retreatment | 2 | 2011 | 610 | 0.130 |
Why?
|
| Double-Blind Method | 9 | 2020 | 12026 | 0.130 |
Why?
|
| Nitrates | 1 | 1996 | 265 | 0.130 |
Why?
|
| Writing | 1 | 2017 | 206 | 0.130 |
Why?
|
| Registries | 6 | 2019 | 8089 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2017 | 3743 | 0.120 |
Why?
|
| Magnesium Sulfate | 1 | 1995 | 68 | 0.120 |
Why?
|
| Hospitals, Veterans | 1 | 2016 | 404 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 20129 | 0.120 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2000 | 585 | 0.120 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2018 | 290 | 0.120 |
Why?
|
| Retrospective Studies | 11 | 2023 | 77449 | 0.120 |
Why?
|
| Digoxin | 1 | 1995 | 250 | 0.120 |
Why?
|
| Adult | 40 | 2019 | 214055 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 15540 | 0.120 |
Why?
|
| Odds Ratio | 7 | 2013 | 9849 | 0.120 |
Why?
|
| Inflammation | 6 | 2009 | 10638 | 0.120 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2023 | 1422 | 0.120 |
Why?
|
| Salicylates | 1 | 2014 | 126 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 5 | 2019 | 5391 | 0.110 |
Why?
|
| Calcinosis | 1 | 2001 | 1499 | 0.110 |
Why?
|
| Regional Blood Flow | 5 | 2009 | 1525 | 0.110 |
Why?
|
| Neopterin | 1 | 2012 | 56 | 0.110 |
Why?
|
| Apolipoproteins B | 2 | 2009 | 374 | 0.100 |
Why?
|
| Edetic Acid | 1 | 1992 | 276 | 0.100 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 19905 | 0.100 |
Why?
|
| Hemodynamics | 6 | 2012 | 4199 | 0.100 |
Why?
|
| Long-Term Care | 1 | 2015 | 607 | 0.100 |
Why?
|
| Thrombosis | 4 | 2012 | 2968 | 0.100 |
Why?
|
| Exercise | 2 | 2018 | 5615 | 0.100 |
Why?
|
| Atherectomy, Coronary | 2 | 2001 | 148 | 0.100 |
Why?
|
| Epoprostenol | 1 | 2012 | 254 | 0.100 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 262 | 0.100 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2012 | 153 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2016 | 7729 | 0.090 |
Why?
|
| Apolipoproteins A | 1 | 1991 | 94 | 0.090 |
Why?
|
| Interleukin-18 | 1 | 2012 | 249 | 0.090 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2010 | 66 | 0.090 |
Why?
|
| Hospitals, Teaching | 2 | 1996 | 1179 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 205 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2012 | 859 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2013 | 497 | 0.090 |
Why?
|
| Family Practice | 4 | 1998 | 516 | 0.090 |
Why?
|
| Device Removal | 2 | 2011 | 656 | 0.090 |
Why?
|
| Receptor, Endothelin A | 3 | 2009 | 58 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 3 | 2014 | 1831 | 0.090 |
Why?
|
| Utilization Review | 1 | 1991 | 392 | 0.080 |
Why?
|
| Energy Intake | 1 | 1997 | 2148 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 3 | 2014 | 2212 | 0.080 |
Why?
|
| Angiography | 2 | 2019 | 1639 | 0.080 |
Why?
|
| Heart Arrest | 2 | 2013 | 1470 | 0.080 |
Why?
|
| Pulmonary Artery | 2 | 2012 | 1912 | 0.080 |
Why?
|
| Aged, 80 and over | 13 | 2015 | 57776 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 638 | 0.080 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 551 | 0.080 |
Why?
|
| Vasodilator Agents | 4 | 2014 | 977 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2014 | 1534 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2013 | 689 | 0.080 |
Why?
|
| Interleukin-6 | 3 | 2013 | 3200 | 0.080 |
Why?
|
| Catheters | 1 | 2011 | 425 | 0.080 |
Why?
|
| Cholesterol, HDL | 4 | 2003 | 1814 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3508 | 0.080 |
Why?
|
| Blood Pressure | 4 | 2003 | 8554 | 0.080 |
Why?
|
| Disease Progression | 8 | 2013 | 13284 | 0.080 |
Why?
|
| Educational Measurement | 1 | 2014 | 1210 | 0.080 |
Why?
|
| Stress, Mechanical | 5 | 2007 | 1686 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 2170 | 0.080 |
Why?
|
| Iliac Artery | 2 | 2007 | 364 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 1477 | 0.070 |
Why?
|
| Cohort Studies | 6 | 2015 | 40561 | 0.070 |
Why?
|
| Endocarditis, Bacterial | 1 | 2011 | 455 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 642 | 0.070 |
Why?
|
| Forecasting | 1 | 2016 | 2951 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 1992 | 1364 | 0.070 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2009 | 426 | 0.070 |
Why?
|
| Peptides, Cyclic | 3 | 2009 | 400 | 0.070 |
Why?
|
| Physical Therapy Modalities | 1 | 1991 | 550 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2011 | 1184 | 0.070 |
Why?
|
| Heart Conduction System | 1 | 2012 | 1047 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 1988 | 440 | 0.070 |
Why?
|
| Triglycerides | 4 | 2003 | 2454 | 0.070 |
Why?
|
| Tachycardia, Ventricular | 1 | 1995 | 1273 | 0.070 |
Why?
|
| Azetidines | 1 | 2007 | 142 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1996 | 2268 | 0.070 |
Why?
|
| Phospholipids | 1 | 2009 | 784 | 0.070 |
Why?
|
| Prosthesis-Related Infections | 1 | 2011 | 538 | 0.070 |
Why?
|
| Prognosis | 5 | 2024 | 29063 | 0.060 |
Why?
|
| Preventive Medicine | 1 | 1987 | 264 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2010 | 15295 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 1991 | 722 | 0.060 |
Why?
|
| Patient Selection | 3 | 2012 | 4215 | 0.060 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2010 | 591 | 0.060 |
Why?
|
| Mass Screening | 3 | 1990 | 5255 | 0.060 |
Why?
|
| Anaphylaxis | 1 | 2012 | 746 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2010 | 761 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2005 | 1889 | 0.060 |
Why?
|
| Exercise Test | 3 | 2018 | 2074 | 0.060 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 3610 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 14722 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 2282 | 0.060 |
Why?
|
| Oxidative Stress | 3 | 2006 | 3086 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2007 | 836 | 0.060 |
Why?
|
| Incidence | 5 | 2013 | 20947 | 0.060 |
Why?
|
| Stroke Volume | 3 | 2024 | 5007 | 0.060 |
Why?
|
| Professional Review Organizations | 2 | 2012 | 50 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2008 | 2618 | 0.050 |
Why?
|
| Solubility | 1 | 2004 | 1085 | 0.050 |
Why?
|
| Echocardiography | 2 | 2011 | 5102 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 12788 | 0.050 |
Why?
|
| omega-N-Methylarginine | 1 | 2001 | 111 | 0.050 |
Why?
|
| Compliance | 1 | 2001 | 104 | 0.050 |
Why?
|
| Defibrillators, Implantable | 1 | 2011 | 1440 | 0.050 |
Why?
|
| Animals | 9 | 2022 | 168757 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2001 | 121 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 2077 | 0.050 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2001 | 141 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 2 | 1998 | 1602 | 0.050 |
Why?
|
| Apolipoproteins | 1 | 2003 | 317 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 1537 | 0.050 |
Why?
|
| Contrast Media | 2 | 2012 | 5300 | 0.050 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2012 | 194 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2011 | 6459 | 0.050 |
Why?
|
| Blood Coagulation | 2 | 2024 | 1127 | 0.050 |
Why?
|
| Total Quality Management | 2 | 2012 | 274 | 0.050 |
Why?
|
| Insulin | 1 | 2015 | 6580 | 0.050 |
Why?
|
| Prospective Studies | 6 | 2023 | 53288 | 0.050 |
Why?
|
| Heart Diseases | 2 | 1990 | 2788 | 0.040 |
Why?
|
| ROC Curve | 1 | 2007 | 3527 | 0.040 |
Why?
|
| Elasticity | 1 | 2001 | 657 | 0.040 |
Why?
|
| Kidney | 1 | 2015 | 7186 | 0.040 |
Why?
|
| Troponin | 1 | 2003 | 524 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 2029 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2011 | 3821 | 0.040 |
Why?
|
| Terrorism | 1 | 2002 | 211 | 0.040 |
Why?
|
| Pyridones | 1 | 2024 | 712 | 0.040 |
Why?
|
| Developing Countries | 2 | 2003 | 2815 | 0.040 |
Why?
|
| Autoantibodies | 2 | 2009 | 2035 | 0.040 |
Why?
|
| Inguinal Canal | 1 | 2019 | 69 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 1998 | 55 | 0.040 |
Why?
|
| Linear Models | 4 | 2013 | 5952 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1991 | 1681 | 0.040 |
Why?
|
| Hypertension | 2 | 2012 | 8480 | 0.040 |
Why?
|
| Radiography | 1 | 2009 | 7023 | 0.040 |
Why?
|
| Health Behavior | 1 | 1990 | 2636 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 916 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2002 | 673 | 0.040 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1987 | 1008 | 0.040 |
Why?
|
| Massachusetts | 1 | 2011 | 8663 | 0.040 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2001 | 314 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2001 | 642 | 0.040 |
Why?
|
| Consensus | 2 | 2017 | 2959 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2001 | 432 | 0.040 |
Why?
|
| Medicare | 1 | 2015 | 6566 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2022 | 9146 | 0.040 |
Why?
|
| Wettability | 1 | 1996 | 24 | 0.040 |
Why?
|
| Ultrasonography | 4 | 2005 | 5985 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 1996 | 56 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2010 | 2758 | 0.040 |
Why?
|
| Absorption | 1 | 1996 | 248 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8642 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1990 | 3022 | 0.030 |
Why?
|
| Cost Allocation | 1 | 1996 | 51 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 10943 | 0.030 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7659 | 0.030 |
Why?
|
| Ankle | 1 | 2019 | 327 | 0.030 |
Why?
|
| Thrombectomy | 1 | 2001 | 680 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 2274 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2001 | 818 | 0.030 |
Why?
|
| Benchmarking | 2 | 2012 | 1042 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2013 | 707 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 7913 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 5137 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 1998 | 365 | 0.030 |
Why?
|
| Physician's Role | 1 | 2002 | 943 | 0.030 |
Why?
|
| Cholestyramine Resin | 1 | 1994 | 24 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 1996 | 207 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2011 | 1133 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 1541 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1998 | 732 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2001 | 1359 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2024 | 1972 | 0.030 |
Why?
|
| Rest | 1 | 2018 | 901 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2001 | 1248 | 0.030 |
Why?
|
| Health Services | 1 | 1998 | 758 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 6895 | 0.030 |
Why?
|
| San Francisco | 1 | 2012 | 159 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 1420 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1993 | 588 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 1998 | 820 | 0.030 |
Why?
|
| Neutropenia | 1 | 1997 | 895 | 0.030 |
Why?
|
| Ambulances | 1 | 2012 | 95 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2019 | 906 | 0.030 |
Why?
|
| Lipids | 3 | 2005 | 3305 | 0.030 |
Why?
|
| Observer Variation | 2 | 2013 | 2593 | 0.020 |
Why?
|
| Drainage, Postural | 1 | 1991 | 1 | 0.020 |
Why?
|
| Urban Health Services | 1 | 2012 | 179 | 0.020 |
Why?
|
| Percussion | 1 | 1991 | 18 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 2011 | 171 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2012 | 127 | 0.020 |
Why?
|
| Patient Care Team | 2 | 2012 | 2531 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 3798 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 4328 | 0.020 |
Why?
|
| Suction | 1 | 2011 | 267 | 0.020 |
Why?
|
| Heart Rate | 2 | 2003 | 4091 | 0.020 |
Why?
|
| Water | 1 | 1996 | 1395 | 0.020 |
Why?
|
| Education, Medical, Graduate | 2 | 2012 | 2291 | 0.020 |
Why?
|
| Fever | 1 | 1997 | 1616 | 0.020 |
Why?
|
| Patient Admission | 1 | 1997 | 1380 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 981 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1991 | 623 | 0.020 |
Why?
|
| North America | 1 | 2013 | 1249 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2010 | 155 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 35421 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 3 | 2011 | 7181 | 0.020 |
Why?
|
| Community Health Nursing | 1 | 1988 | 24 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 3843 | 0.020 |
Why?
|
| Sputum | 1 | 1991 | 476 | 0.020 |
Why?
|
| Reagent Strips | 1 | 1988 | 39 | 0.020 |
Why?
|
| Photometry | 1 | 1988 | 58 | 0.020 |
Why?
|
| Peptides | 1 | 2001 | 4409 | 0.020 |
Why?
|
| Pneumonia | 1 | 2000 | 2133 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2012 | 783 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1994 | 1681 | 0.020 |
Why?
|
| Smoking | 3 | 2003 | 8987 | 0.020 |
Why?
|
| Troponin I | 1 | 2012 | 619 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1998 | 2684 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2009 | 21746 | 0.020 |
Why?
|
| South Africa | 1 | 2013 | 1731 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 25043 | 0.020 |
Why?
|
| Emergencies | 1 | 2013 | 1170 | 0.020 |
Why?
|
| Hemorheology | 1 | 2007 | 145 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2012 | 1609 | 0.020 |
Why?
|
| Emergency Medical Services | 2 | 2012 | 1917 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3339 | 0.020 |
Why?
|
| Cost of Illness | 1 | 1996 | 1859 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2012 | 1462 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 2971 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 2005 | 65 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2019 | 3209 | 0.020 |
Why?
|
| Heart Atria | 1 | 2011 | 1357 | 0.020 |
Why?
|
| Insulin Resistance | 2 | 2014 | 3864 | 0.020 |
Why?
|
| Catheterization | 1 | 2010 | 1470 | 0.020 |
Why?
|
| Primary Prevention | 1 | 1992 | 1167 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 1286 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 2009 | 4560 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 1537 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1738 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2001 | 8949 | 0.010 |
Why?
|
| Diet Therapy | 1 | 2005 | 154 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 2187 | 0.010 |
Why?
|
| Health Education | 1 | 1990 | 1056 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 2003 | 124 | 0.010 |
Why?
|
| Egypt | 1 | 2003 | 100 | 0.010 |
Why?
|
| Equipment Design | 1 | 2011 | 3582 | 0.010 |
Why?
|
| Adolescent | 4 | 2002 | 85781 | 0.010 |
Why?
|
| Hospitalization | 2 | 2012 | 10262 | 0.010 |
Why?
|
| Thromboembolism | 1 | 2009 | 986 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6538 | 0.010 |
Why?
|
| Dyspnea | 1 | 2010 | 1303 | 0.010 |
Why?
|
| Thailand | 1 | 2003 | 296 | 0.010 |
Why?
|
| Philosophy, Medical | 1 | 2002 | 79 | 0.010 |
Why?
|
| Sex Factors | 2 | 1997 | 10397 | 0.010 |
Why?
|
| Beta Particles | 1 | 2001 | 50 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2005 | 4042 | 0.010 |
Why?
|
| Reference Values | 1 | 1988 | 4982 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1997 | 13989 | 0.010 |
Why?
|
| Phagocytes | 1 | 2002 | 297 | 0.010 |
Why?
|
| Forearm | 1 | 2003 | 409 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2002 | 647 | 0.010 |
Why?
|
| Platelet Function Tests | 1 | 2002 | 270 | 0.010 |
Why?
|
| Kenya | 1 | 2003 | 685 | 0.010 |
Why?
|
| Schools, Medical | 1 | 1987 | 880 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1984 | 850 | 0.010 |
Why?
|
| Simvastatin | 1 | 2002 | 360 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2002 | 464 | 0.010 |
Why?
|
| Biological Availability | 1 | 2000 | 397 | 0.010 |
Why?
|
| Infant Mortality | 1 | 1984 | 754 | 0.010 |
Why?
|
| Child | 3 | 2012 | 77709 | 0.010 |
Why?
|
| Teaching | 1 | 1987 | 1174 | 0.010 |
Why?
|
| Bibliometrics | 1 | 2003 | 339 | 0.010 |
Why?
|
| Age Factors | 2 | 1997 | 18370 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1991 | 3188 | 0.010 |
Why?
|
| Living Donors | 1 | 2002 | 620 | 0.010 |
Why?
|
| Length of Stay | 2 | 1997 | 6309 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1991 | 3966 | 0.010 |
Why?
|
| Hirudins | 1 | 1999 | 183 | 0.010 |
Why?
|
| Publications | 1 | 2000 | 195 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1991 | 3528 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2001 | 415 | 0.010 |
Why?
|
| Perfusion | 1 | 2002 | 1360 | 0.010 |
Why?
|
| Oncology Service, Hospital | 1 | 1997 | 57 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1998 | 401 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 12959 | 0.010 |
Why?
|
| China | 1 | 2003 | 2248 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2000 | 1572 | 0.010 |
Why?
|
| India | 1 | 2003 | 2197 | 0.010 |
Why?
|
| Telemedicine | 1 | 2013 | 2872 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 1504 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 789 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 4258 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 1836 | 0.010 |
Why?
|
| Macrophages | 2 | 2002 | 5655 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1997 | 694 | 0.010 |
Why?
|
| Publishing | 1 | 2003 | 833 | 0.010 |
Why?
|
| International Cooperation | 1 | 2002 | 1420 | 0.010 |
Why?
|
| Prevalence | 1 | 2012 | 15226 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2000 | 1842 | 0.010 |
Why?
|
| Physicians | 1 | 2013 | 4567 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 1518 | 0.010 |
Why?
|
| Students, Medical | 1 | 1987 | 1862 | 0.010 |
Why?
|
| Curriculum | 1 | 1987 | 3605 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 4894 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1997 | 1588 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 1390 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 5078 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 4149 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2000 | 2453 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1997 | 1227 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1997 | 1726 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 4568 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2001 | 1373 | 0.010 |
Why?
|
| Diet | 1 | 1990 | 7939 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 2003 | 1432 | 0.010 |
Why?
|
| Heparin | 1 | 1999 | 1637 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2002 | 2508 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 2000 | 2161 | 0.010 |
Why?
|
| Cross Infection | 1 | 2000 | 1416 | 0.010 |
Why?
|
| Pyridines | 1 | 2002 | 2825 | 0.010 |
Why?
|
| Bacteremia | 1 | 1997 | 962 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 8324 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 6622 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2001 | 2872 | 0.010 |
Why?
|
| Obesity | 1 | 1991 | 12745 | 0.010 |
Why?
|
| Neoplasms | 1 | 1997 | 21683 | 0.000 |
Why?
|
| Cytokines | 1 | 2002 | 7322 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 2002 | 13033 | 0.000 |
Why?
|
| Stress, Psychological | 1 | 2002 | 4245 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2002 | 19229 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1999 | 5097 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1984 | 518 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 10180 | 0.000 |
Why?
|
| Developmental Disabilities | 1 | 1984 | 1456 | 0.000 |
Why?
|
| Mice | 1 | 2002 | 81183 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1997 | 13695 | 0.000 |
Why?
|
| Health Status | 1 | 1984 | 4034 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 1984 | 7785 | 0.000 |
Why?
|
| Patient Readmission | 1 | 1984 | 3114 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1984 | 25625 | 0.000 |
Why?
|